Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy

Table 6 Adverse events associated with sintilimab plus chemotherapy in gastric cancer patients, n (%)

Variables	Low TyG index (n = 164)	High TyG index (n = 136)	χ2	P value
All grades: Leukopenia	71 (43.29)	62 (45.59)	0.26	0.607
All grades: Anemia	68 (41.46)	58 (42.65)	0.00	0.989
All grades: Neutropenia	63 (38.41)	50 (36.75)	0.09	0.769
All grades: Thrombocytopenia	58 (35.37)	47 (34.56)	0.00	0.959
All grades: Nausea	50 (30.49)	38 (27.94)	0.23	0.630
All grades: Pyrexia	40 (24.39)	36 (26.47)	0.17	0.680
All grades: Elevated ALT	34 (20.73)	24 (17.65)	0.45	0.501
All grades: Elevated AST	34 (20.73)	22 (16.18)	1.02	0.313
All grades: Hypothyroidism	32 (19.51)	31 (22.79)	0.48	0.487
All grades: Diarrhea	29 (17.68)	32 (23.52)	1.57	0.210
All grades: Hypertension	24 (14.63)	19 (13.97)	0.03	0.870
All grades: Pneumonitis	20 (12.20)	17 (12.50)	0.02	0.898
All grades: Proteinuria	18 (10.98)	12 (8.82)	0.38	0.536
All grades: Hyperbilirubinemia	17 (10.37)	12 (8.82)	0.20	0.653
All grades: Fatigue	16 (9.80)	13 (10.29)	0.00	0.954
≥ 3 grades: Thrombocytopenia	30 (18.29)	22 (16.18)	0.23	0.630
≥ 3 grades: Neutropenia	21 (12.80)	14 (10.29)	0.45	0.500
≥ 3 grades: Leukopenia	19 (11.59)	15 (11.03)	0.02	0.880
≥ 3 grades: Anemia	15 (9.15)	10 (7.35)	0.31	0.576
≥ 3 grades: Diarrhea	8 (4.88)	6 (4.41)	0.04	0.849
≥ 3 grades: Nausea	7 (4.27)	5 (3.68)	0.07	0.795
≥ 3 grades: Elevated ALT	5 (3.05)	4 (2.94)	0.08	0.775
≥ 3 grades: Elevated AST	4 (5.88)	2 (1.47)	0.03	0.855
≥ 3 grades: Hypothyroidism	3 (1.83)	4 (2.94)	0.04	0.833
≥ 3 grades: Hypertension	3 (1.83)	2 (1.47)	0.05	0.819
≥ 3 grades: Pneumonitis	3 (1.83)	2 (1.47)	0.05	0.819
≥ 3 grades: Hyperbilirubinemia	2 (1.22)	2 (1.47)	0.09	0.763
≥ 3 grades: Fatigue	0 (0.00)	0 (0.00)	-	-
≥ 3 grades: Pyrexia	0 (0.00)	0 (0.00)	-	-
≥ 3 grades: Proteinuria	0 (0.00)	0 (0.00)	-	-

TyG: Triglyceride glucose; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.